
    
      In Cycle 1, participants will receive double-blind study drug (fosaprepitant plus ondansetron
      with or without dexamethasone OR placebo to fosaprepitant plus ondansetron with or without
      dexamethasone). Upon completion of Cycle 1, participants may have the option to continue for
      up to 5 additional open-label cycles, receiving fosaprepitant plus ondansetron with or
      without dexamethasone.
    
  